Kenneth Olivier, MD, MPH

Dr. Olivier is the Michael E. Hatcher Distinguished Professor of Medicine, Microbiology and Immunology at the University of North Carolina School of Medicine. He is the Research Director of the UNC Bronchiectasis/NTM Care and Research Center and Co-Director of the PCD Foundation Network for Clinical Trials Leadership Center. He was a site investigator and project lead for the NIH funded Genetic Disorders of Mucociliary Clearance for almost 20 years. He is the current co-lead of the NIH funded Rare Bronchiectatic Diseases Consortium. His research focuses on host susceptibility, pathogenesis and population characteristics of bronchiectasis and chronic airway infection such as the nontuberculous mycobacteria, and he has been actively engaged in preclinical and clinical therapeutics development in these areas. He has authored and coauthored over 200 peer reviewed research papers, review articles and book chapters pertaining to these topics.
Financial relationships
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Mannkind CorporationTopic:Nontuberculous mycobacteriaDate added:02/08/2026Date updated:02/08/2026
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Spero TherapeuticsTopic:Nontuberculous mycobacteriaDate added:02/08/2026Date updated:02/08/2026
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Paratek PharmaTopic:Nontuberculous mycobacteriaDate added:02/08/2026Date updated:02/08/2026
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Insmed, IncTopic:Bronchiectasis, Nontuberculous mycobacteriaDate added:02/08/2026Date updated:02/08/2026
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:AN2 TherapeuticsTopic:Nontuberculous mycobacteriaDate added:02/08/2026Date updated:02/08/2026
-
Attribution:SelfType of financial relationship:Contracted ResearchIneligible company:Verona Pharma/MerckTopic:BronchiectasisDate added:02/08/2026Date updated:02/08/2026
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Beyond AirTopic:Nontuberculous mycobacteriaDate added:02/08/2026Date updated:02/08/2026
-
Attribution:SelfType of financial relationship:Contracted ResearchIneligible company:ReCode TherapeuticsTopic:Primary ciliary dyskinesiaDate added:02/08/2026Date updated:02/08/2026
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:CSL BehringTopic:BronchiectasisDate added:02/08/2026Date updated:02/08/2026
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PCD FoundationTopic:Primary ciliary dyskinesiaDate added:02/08/2026Date updated:02/08/2026

Facebook
X
LinkedIn
Forward